Nothing Special   »   [go: up one dir, main page]

LT3151672T - Patobulintos t ląstelių kompozicijos - Google Patents

Patobulintos t ląstelių kompozicijos

Info

Publication number
LT3151672T
LT3151672T LTEP15802488.5T LT15802488T LT3151672T LT 3151672 T LT3151672 T LT 3151672T LT 15802488 T LT15802488 T LT 15802488T LT 3151672 T LT3151672 T LT 3151672T
Authority
LT
Lithuania
Prior art keywords
improved
cell compositions
compositions
cell
Prior art date
Application number
LTEP15802488.5T
Other languages
English (en)
Inventor
Kevin FRIEDMAN
Original Assignee
Bluebird Bio, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54767459&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3151672(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bluebird Bio, Inc. filed Critical Bluebird Bio, Inc.
Publication of LT3151672T publication Critical patent/LT3151672T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
LTEP15802488.5T 2014-06-06 2015-06-05 Patobulintos t ląstelių kompozicijos LT3151672T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462008957P 2014-06-06 2014-06-06
PCT/US2015/034515 WO2015188119A1 (en) 2014-06-06 2015-06-05 Improved t cell compositions

Publications (1)

Publication Number Publication Date
LT3151672T true LT3151672T (lt) 2021-02-10

Family

ID=54767459

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP15802488.5T LT3151672T (lt) 2014-06-06 2015-06-05 Patobulintos t ląstelių kompozicijos

Country Status (26)

Country Link
US (3) US10479975B2 (lt)
EP (2) EP3828265A1 (lt)
JP (2) JP6663359B2 (lt)
KR (2) KR20230008915A (lt)
CN (2) CN106793780B (lt)
AU (3) AU2015269197B2 (lt)
BR (1) BR112016028644B1 (lt)
CA (1) CA2951044C (lt)
CY (1) CY1123823T1 (lt)
DK (1) DK3151672T3 (lt)
ES (1) ES2846811T3 (lt)
HR (1) HRP20210116T1 (lt)
HU (1) HUE053101T2 (lt)
IL (1) IL249313A0 (lt)
LT (1) LT3151672T (lt)
MX (2) MX2016016076A (lt)
NZ (1) NZ726989A (lt)
PL (1) PL3151672T3 (lt)
PT (1) PT3151672T (lt)
RS (1) RS61406B1 (lt)
RU (1) RU2719030C2 (lt)
SG (3) SG11201610170SA (lt)
SI (1) SI3151672T1 (lt)
SM (1) SMT202100049T1 (lt)
WO (1) WO2015188119A1 (lt)
ZA (2) ZA201608378B (lt)

Families Citing this family (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
MY159955A (en) 2008-01-04 2017-02-15 Intellikine Inc Certain chemical entities, compositions and methods
SG184819A1 (en) * 2010-04-13 2012-11-29 Immunovative Therapies Ltd Methods and compositions for inhibition of treg cells
EP3581574A1 (en) 2011-01-10 2019-12-18 Infinity Pharmaceuticals, Inc. A composition for oral administration for use in the treatment of cancer, an inflammatory disease or an auto-immune disease
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
NZ744567A (en) 2012-11-01 2020-03-27 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
US10774343B2 (en) 2014-04-25 2020-09-15 Bluebird Bio, Inc. MND promoter chimeric antigen receptors
DK3151672T3 (da) * 2014-06-06 2021-02-01 Bluebird Bio Inc Forbedrede t-celle-sammensætninger
WO2016014530A1 (en) * 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
AU2015292590B2 (en) 2014-07-24 2020-01-16 2Seventy Bio, Inc. BCMA chimeric antigen receptors
US20160051669A1 (en) * 2014-08-21 2016-02-25 Georgia Regents University Research Institute, Inc. Compositions and methods for selectively modulating tregs
SI3230321T1 (sl) 2014-12-12 2019-12-31 Bluebird Bio, Inc. BCMA himerni antigenski receptorji
AU2016263176A1 (en) 2015-05-20 2017-12-07 Novartis Ag Pharmaceutical combination of everolimus with dactolisib
WO2017070042A1 (en) * 2015-10-20 2017-04-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of producing t cell populations using akt inhibitors
TWI836160B (zh) 2015-10-20 2024-03-21 美商凱特製藥公司 製備用於ｔ細胞治療之ｔ細胞的方法
CA3004299A1 (en) * 2015-11-05 2017-05-11 City Of Hope Methods for preparing cells for adoptive t cell therapy
WO2017099712A1 (en) 2015-12-07 2017-06-15 Bluebird Bio, Inc. Improved t cell compositions
US11413309B2 (en) 2016-01-20 2022-08-16 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
JP7616817B2 (ja) * 2016-01-20 2025-01-17 フェイト セラピューティクス，インコーポレイテッド 養子免疫療法における免疫細胞調節のための組成物および方法
US11090334B2 (en) 2016-01-29 2021-08-17 Med Manor Organics (P) Ltd. Chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof
US20170216355A1 (en) * 2016-02-02 2017-08-03 Augusta University Research Institute, Inc. Methods and Compositions for Enhancing T Cell Function and Survival
WO2017133175A1 (en) * 2016-02-04 2017-08-10 Nanjing Legend Biotech Co., Ltd. Engineered mammalian cells for cancer therapy
US20200063157A9 (en) * 2016-02-26 2020-02-27 Poseida Therapeutics, Inc. Transposon system and methods of use
US20200281973A1 (en) * 2016-03-04 2020-09-10 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
EP3430158A4 (en) * 2016-03-17 2019-10-23 The University Of British Columbia DEVICES AND METHOD FOR CELL SECRETION ANALYSIS
CN108778312B (zh) * 2016-04-08 2022-07-15 爱默蕾大学 使用基于细胞的疗法治疗癌症和传染病的方法
IL312206A (en) * 2016-04-15 2024-06-01 Novartis Ag Compositions and methods for selective protein expression
CN105907790A (zh) * 2016-06-21 2016-08-31 林志国 特异性识别EGFRvⅢ的含CD70嵌合抗原受体修饰T细胞的制备方法
SG11201811237WA (en) 2016-06-24 2019-01-30 Infinity Pharmaceuticals Inc Combination therapies
EP3494138A1 (en) * 2016-08-02 2019-06-12 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
EP3500696A4 (en) 2016-08-16 2020-04-08 Bluebird Bio, Inc. IL-10 RECEPTOR ALPHA HOMING ENDONUCLEASE VARIANTS, COMPOSITIONS AND METHODS FOR USE
CN106222201B (zh) * 2016-08-27 2017-11-28 北京艺妙神州医疗科技有限公司 一种制备car‑t细胞的方法以及制得的car‑t细胞及其应用
KR20190082241A (ko) 2016-11-04 2019-07-09 블루버드 바이오, 인코포레이티드. 항-bcma car t 세포 조성물
CN110114070A (zh) 2016-11-23 2019-08-09 诺华公司 使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法
WO2018102397A1 (en) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes for delivery of therapeutic agents
EP3548049A4 (en) 2016-12-05 2020-07-22 Fate Therapeutics, Inc. COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE CELLS IN ADOPTIVE IMMUNOTHERAPIES
US20190343954A1 (en) * 2016-12-07 2019-11-14 Transtarget, Inc. Methods and compositions for vaccinating and boosting cancer patients
CN110582509A (zh) 2017-01-31 2019-12-17 诺华股份有限公司 使用具有多特异性的嵌合t细胞受体蛋白治疗癌症
WO2018143454A1 (ja) * 2017-02-06 2018-08-09 国立研究開発法人国立がん研究センター 新規ｔ細胞受容体
CA3054104A1 (en) * 2017-03-27 2018-10-04 F. Hoffmann-La Roche Ag Improved antigen binding receptor formats
BR112019020001A2 (pt) 2017-03-27 2020-04-28 Nat Univ Singapore linhagens celulares estimuladoras para expansão ex vivo e ativação de células exterminadoras naturais
CN117384929A (zh) * 2017-03-27 2024-01-12 新加坡国立大学 一种编码由细胞表达的嵌合受体的多核苷酸
US11596655B2 (en) * 2017-04-27 2023-03-07 Washington University Activation of natural cytotoxicity receptor 2 (NCR2)
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
WO2018201051A1 (en) 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
CN107236762A (zh) * 2017-06-19 2017-10-10 河北浓孚雨生物科技有限公司 一种微环dna转染t细胞制备临床级car‑t细胞制剂的方法
EP3645708A4 (en) 2017-06-30 2021-06-23 Memorial Sloan-Kettering Cancer Center COMPOSITIONS AND METHODS OF ADOPTIVE CELL THERAPY FOR CANCER
EP3654986A2 (en) * 2017-07-19 2020-05-27 Fate Therapeutics, Inc. Compositions and methods for immune cell modulation in adoptive immunotherapies
CN109306013B (zh) * 2017-07-26 2020-09-25 重庆精准生物技术有限公司 抗cd20抗原的嵌合抗原受体及其应用
MX2020002611A (es) 2017-09-07 2020-07-13 Univ Res Inst Inc Augusta Activador especifico de akt3 y usos del mismo.
CN111433354A (zh) * 2017-09-26 2020-07-17 朗沃德大学 作为免疫疗法的pd1特异性嵌合抗原受体
AU2018351050A1 (en) 2017-10-18 2020-05-07 Novartis Ag Compositions and methods for selective protein degradation
WO2019084234A1 (en) * 2017-10-26 2019-05-02 St. Jude Childen's Research Hospital, Inc. METHODS AND COMPOSITIONS FOR TREATING CD33 + CANCERS AND IMPROVING IN VIVO PERSISTENCE OF CHIMERIC ANTIGEN RECEPTOR T CELLS
US20210254000A1 (en) * 2017-11-01 2021-08-19 Juno Therapeutics, Inc. Process for producing a t cell composition
CN107893055B (zh) * 2017-11-03 2020-07-17 深圳市默赛尔生物医学科技发展有限公司 一种特异性嵌合抗原受体基因修饰的自然杀伤细胞及其制备方法和用途
SG11202004512XA (en) 2017-11-15 2020-06-29 Novartis Ag Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
CA3083118A1 (en) * 2017-11-22 2019-05-31 Iovance Biotherapeutics, Inc. Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
RU2020121458A (ru) 2017-11-30 2021-12-30 Новартис Аг Химерный антигенный рецептор, нацеливающийся на bcma, и его пути применения
US11639496B2 (en) 2017-12-05 2023-05-02 Celyad S.A. Reducing fratricide of immune cells expressing NKG2D-based receptors
US20200368268A1 (en) 2018-01-08 2020-11-26 Novartis Ag Immune-enhancing rnas for combination with chimeric antigen receptor therapy
US10561686B2 (en) * 2018-01-12 2020-02-18 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
WO2019152660A1 (en) 2018-01-31 2019-08-08 Novartis Ag Combination therapy using a chimeric antigen receptor
US20200399383A1 (en) 2018-02-13 2020-12-24 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
KR20200130709A (ko) * 2018-03-06 2020-11-19 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 전립선-특이 막 항원 car 및 이의 사용 방법
CN110272481A (zh) * 2018-03-14 2019-09-24 中国科学院广州生物医药与健康研究院 识别mage1抗原短肽的t细胞受体
US11246890B2 (en) 2018-04-03 2022-02-15 The Board Of Trustees Of The Leland Stanford Junior University Systemic targeting of inflammatory sites and enhanced immunomodulatory function by introducing the chimeric antigen receptor (CAR) into mesenchymal stem cells for inflammatory and autoimmune diseases
US10869888B2 (en) 2018-04-17 2020-12-22 Innovative Cellular Therapeutics CO., LTD. Modified cell expansion and uses thereof
US20210371852A1 (en) * 2018-05-18 2021-12-02 Children's National Medical Center System of cell expansion and methods of using the same
WO2019241688A1 (en) * 2018-06-14 2019-12-19 Bluebird Bio, Inc. Cd79b chimeric antigen receptors
BR112020025439A2 (pt) 2018-06-14 2021-03-16 Bluebird Bio, Inc. Receptores de antígenos quiméricos cd79a
WO2019242632A1 (en) * 2018-06-19 2019-12-26 1§1Nanjing Legend Biotech Co., Ltd. Engineered cells and uses thereof
US20220348682A1 (en) 2018-08-30 2022-11-03 Innovative Cellular Therapeutics Holdings, Ltd. Chimeric antigen receptor cells for treating solid tumor
US20210171909A1 (en) 2018-08-31 2021-06-10 Novartis Ag Methods of making chimeric antigen receptor?expressing cells
US20220364055A1 (en) 2018-08-31 2022-11-17 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
KR20210056377A (ko) * 2018-09-07 2021-05-18 소티오, 엘엘씨 세포내 락테이트 농도를 조절하는 트랜스 대사 분자와 조합된 키메라 수용체 폴리펩타이드 및 이의 치료 용도
EP3877511A1 (en) * 2018-11-05 2021-09-15 Iovance Biotherapeutics, Inc. Expansion of tils utilizing akt pathway inhibitors
WO2020097236A1 (en) * 2018-11-06 2020-05-14 Board Of Regents, The University Of Texas System Fgl2 neutraling cell therapy and methods of use thereof
WO2020102701A1 (en) * 2018-11-16 2020-05-22 Rapa Therapeutics, Llc Methods for the manufacture of th1/tc1 phenotype t cells
US10918667B2 (en) 2018-11-20 2021-02-16 Innovative Cellular Therapeutics CO., LTD. Modified cell expressing therapeutic agent and uses thereof
US12076344B2 (en) * 2018-11-30 2024-09-03 The Medical College Of Wisconsin, Inc. T-Rapa cells as novel effector cell type for chimeric antigen receptor therapy
CN109694884A (zh) * 2019-01-09 2019-04-30 上海美丽人生医疗科技有限公司 用于在结肠癌治疗中应用的car-t载体的制备及其构建方法
SG11202107825WA (en) 2019-02-25 2021-09-29 Novartis Ag Mesoporous silica particles compositions for viral delivery
US20230074800A1 (en) 2019-03-21 2023-03-09 Novartis Ag Car-t cell therapies with enhanced efficacy
KR20220031541A (ko) 2019-04-05 2022-03-11 2세븐티 바이오, 인코포레이티드 항-bcma car t 세포의 제조
WO2020210678A1 (en) 2019-04-12 2020-10-15 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
EP3959320A1 (en) 2019-04-24 2022-03-02 Novartis AG Compositions and methods for selective protein degradation
AU2020288888A1 (en) * 2019-06-06 2022-01-27 President And Fellows Of Harvard College Cardiomyocytes and compositions and methods for producing the same
CN110229236B (zh) * 2019-06-13 2023-06-09 郑州大学第一附属医院 诱导肿瘤细胞上调抗原muc1表达用car及其应用
US20210220404A1 (en) 2019-11-26 2021-07-22 Novartis Ag Chimeric antigen receptors and uses thereof
KR102539610B1 (ko) * 2020-01-22 2023-06-02 한국생명공학연구원 메모리 b 세포 특이적 분화 유도 방법 및 이의 활용
US12076343B2 (en) 2020-02-19 2024-09-03 Innovative Cellular Therapeutics Holdings, Ltd. Engineered safety in cell therapy
IL295604A (en) 2020-02-27 2022-10-01 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
KR20220147109A (ko) 2020-02-27 2022-11-02 노파르티스 아게 키메라 항원 수용체 발현 세포의 제조 방법
KR102387595B1 (ko) * 2020-03-23 2022-04-15 연세대학교 산학협력단 면역 세포의 면역 기능 향상을 위한 방법 및 이에 따른 면역 세포주
GB202005617D0 (en) * 2020-04-17 2020-06-03 Adaptimmune Ltd Improved t cell manufacturing process
US12043654B2 (en) 2020-06-02 2024-07-23 Innovative Cellular Therapeutics Holdings, Ltd. Anti-GCC antibody and CAR thereof for treating digestive system cancer
CN116096862A (zh) 2020-06-11 2023-05-09 诺华股份有限公司 Zbtb32抑制剂及其用途
US20230190804A1 (en) * 2020-06-17 2023-06-22 Tiziana Life Sciences Plc Compositions and methods for augmenting chimeric antigen receptor (car) t cell therapies
BR112022026899A2 (pt) 2020-07-20 2023-01-24 Enanta Pharm Inc Composto representado pela fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método de tratamento ou prevenção de uma infecção por vírus, método de inibição da protease 3c viral ou protease 3cl viral em um mamífero e método de tratamento de um distúrbio respiratório
TW202227124A (zh) 2020-08-21 2022-07-16 瑞士商諾華公司 用於體內產生ｃａｒ表現細胞的組成物和方法
CN114426952A (zh) * 2020-10-29 2022-05-03 中国科学技术大学 用于白血病的car t细胞疗法的t细胞增效剂及获得增效t细胞的方法
US11352363B1 (en) 2020-11-23 2022-06-07 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
MX2023005983A (es) 2020-11-23 2023-08-15 Enanta Pharm Inc Nuevos agentes antivirales derivados de la espiropirrolidina.
US11384090B2 (en) 2020-11-23 2022-07-12 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
CA3172530A1 (en) 2021-02-25 2022-09-01 Spencer PARK Ror1 targeting chimeric antigen receptor
US20240384293A1 (en) 2021-04-27 2024-11-21 Novartis Ag Viral vector production system
TW202309071A (zh) 2021-05-05 2023-03-01 德商英麥提克生物技術股份有限公司 特異性結合ｐｒａｍｅ之抗原結合蛋白
US11319325B1 (en) 2021-05-11 2022-05-03 Enanta Pharmaceuticals, Inc. Macrocyclic spiropyrrolidine derived antiviral agents
US11339170B1 (en) 2021-07-23 2022-05-24 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US11325916B1 (en) 2021-07-29 2022-05-10 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
WO2023021477A1 (en) 2021-08-20 2023-02-23 Novartis Ag Methods of making chimeric antigen receptor–expressing cells
WO2024089639A1 (en) 2022-10-26 2024-05-02 Novartis Ag Lentiviral formulations
WO2024097793A1 (en) * 2022-11-04 2024-05-10 The Regents Of The University Of California Method for manufacturing therapeutic immune cells
WO2024107646A1 (en) * 2022-11-14 2024-05-23 Caribou Biosciences, Inc. Anti-cll-1 chimeric antigen receptors, engineered cells and related methods
WO2024112867A1 (en) 2022-11-23 2024-05-30 University Of Georgia Research Foundation, Inc. Compositions and methods of use thereof for increasing immune responses

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873192A (en) 1987-02-17 1989-10-10 The United States Of America As Represented By The Department Of Health And Human Services Process for site specific mutagenesis without phenotypic selection
ES2054778T3 (es) 1988-01-09 1994-08-16 Asta Medica Ag Complejos de 1,2-bis (aminometil) ciclobutano-platino.
US7479269B2 (en) 1988-11-23 2009-01-20 Genetics Institute, Llc Methods for selectively enriching TH1 and TH2 cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
DK1621554T4 (da) 1992-08-21 2012-12-17 Univ Bruxelles Immunoglobuliner blottet for lette kæder
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
DE4415263C1 (de) 1994-04-15 1995-11-30 Asta Medica Ag Cis-[trans-1,2-Cyclobutanbis(methylamin)-N,N']-[(2S)-lactato-O·1·, O·2·]-platin(II)-trihydrat (Lobaplatin-Trihydrat), seine Herstellung und arzneiliche Verwendung
US6632789B1 (en) * 1994-04-29 2003-10-14 The United States Of America As Represented By The Secretary Of The Navy Methods for modulating T cell responses by manipulating intracellular signal transduction
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
WO1997032970A1 (en) 1996-03-04 1997-09-12 Targeted Genetics Corporation Modified rapid expansion methods ('modified-rem') for in vitro propagation of t lymphocytes
US20020177125A1 (en) 1997-03-04 2002-11-28 Kamb Carl Alexander Human rhinovirus assays, and compositions therefrom
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
FR2777909B1 (fr) 1998-04-24 2002-08-02 Pasteur Institut Utilisation de sequences d'adn de structure triplex pour le tranfert de sequences de nucleotides dans des cellules, vecteurs recombinants contenant ces sequences triplex
BR0108545A (pt) 2000-02-24 2004-06-29 Xcyte Therapies Inc Estimulação e concentração simultâneas das células
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
EP2301971A1 (en) 2001-02-20 2011-03-30 ZymoGenetics, L.L.C. Antibodies that bind both BCMA and TACI
AU2002257420A1 (en) 2001-05-01 2002-11-11 National Research Council Of Canada A system for inducible expression in eukaryotic cells
DE10132502A1 (de) 2001-07-05 2003-01-23 Gsf Forschungszentrum Umwelt Angriff auf Tumorzellen mit fehlender, niedriger oder anormaler MHC-Expression durch kombinieren von nicht MHC-Restringierten T-Zellen/NK-Zellen und MHC-Restringierten Zellen
US7638325B2 (en) 2002-01-03 2009-12-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform
CA2501940A1 (en) * 2002-10-09 2004-04-22 Tolerrx, Inc. Molecules preferentially associated with effector t cells or regulatory t cells and methods of their use
GB0224442D0 (en) 2002-10-21 2002-11-27 Molmed Spa A delivery system
TW200502391A (en) 2003-05-08 2005-01-16 Xcyte Therapies Inc Generation and isolation of antigen-specific t cells
EP1765988B1 (en) 2004-05-27 2017-09-20 The Trustees of The University of Pennsylvania Novel artificial antigen presenting cells and uses therefor
FR2872170B1 (fr) 2004-06-25 2006-11-10 Centre Nat Rech Scient Cnrse Lentivirus non interactif et non replicatif, preparation et utilisations
WO2006039500A2 (en) 2004-09-29 2006-04-13 California Institute Of Technology Multi-element phased array transmitter with lo phase shifting and integrated power amplifier
GB0503936D0 (en) * 2005-02-25 2005-04-06 San Raffaele Centro Fond Method
AU2006251621A1 (en) 2005-05-20 2006-11-30 Virxsys Corporation Transduction of primary cells
WO2007018318A1 (ja) 2005-08-10 2007-02-15 National University Corporation Kanazawa University 小脳星状細胞及び／又は籠細胞特異的な遺伝子発現方法
JP2010512738A (ja) * 2006-12-14 2010-04-30 メディカル リサーチ カウンシル 方法及び使用
JP5666903B2 (ja) 2007-05-23 2015-02-12 サンガモ バイオサイエンシーズ， インコーポレイテッド 導入遺伝子の発現を増強するための方法および組成物
WO2009091826A2 (en) 2008-01-14 2009-07-23 The Board Of Regents Of The University Of Texas System Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
JP2012501180A (ja) 2008-08-26 2012-01-19 シティ・オブ・ホープ Ｔ細胞の抗腫瘍エフェクター機能増進のための方法および組成物
PL2172211T3 (pl) * 2008-10-01 2015-05-29 Immatics Biotechnologies Gmbh Kompozycja związanych z guzem peptydów i związana z tym szczepionka przeciwrakowa do leczenia glejaka (GBM) i innych rodzajów raka
DK2406284T5 (en) 2009-03-10 2017-06-12 Biogen Ma Inc ANTI-BCMA ANTIBODIES
AU2010301042B2 (en) 2009-10-01 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
EP2496698B1 (en) 2009-11-03 2019-01-09 City of Hope TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRANSDUCED T CELL SELECTION
US8999398B2 (en) 2009-11-06 2015-04-07 Transtarget Inc. Polyclonal bispecific antibody compositions and method of use
GB201004200D0 (en) 2010-03-15 2010-04-28 Univ Basel Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
WO2012033885A1 (en) 2010-09-08 2012-03-15 Baylor College Of Medicine Immunotherapy of cancer using genetically engineered gd2-specific t cells
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
SG192010A1 (en) * 2011-01-18 2013-08-30 Univ Pennsylvania Compositions and methods for treating cancer
US20160002601A1 (en) 2011-03-03 2016-01-07 Stempeutics Research Pvt. Ltd. Methods of upscaling mesenchymal stromal cell production, compositions and kit thereof
CN103502438A (zh) 2011-03-23 2014-01-08 弗雷德哈钦森癌症研究中心 用于细胞免疫治疗的方法和组合物
JP2014514927A (ja) 2011-04-13 2014-06-26 イミュニカム・エイビイ 抗原特異的ｔ細胞の増殖のための方法
US20140105915A1 (en) 2011-05-27 2014-04-17 Glaxo Group Limited Bcma (cd269/tnfrsf17) - binding proteins
US9789139B2 (en) 2011-06-10 2017-10-17 Bluebird Bio, Inc. Gene therapy vectors for adrenoleukodystrophy and adrenomyeloneuropathy
JP5802510B2 (ja) * 2011-09-30 2015-10-28 富士フイルム株式会社 パターン形成方法、感電子線性又は感極紫外線性樹脂組成物、及び、レジスト膜、並びに、これらを用いた電子デバイスの製造方法
WO2013070468A1 (en) 2011-11-08 2013-05-16 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
US10040846B2 (en) 2012-02-22 2018-08-07 The Trustees Of The University Of Pennsylvania Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer
BR112014024893B8 (pt) 2012-04-11 2022-09-06 Us Health Sequência de ácido nucleico isolada ou purificada que codifica um receptor de antígeno quimérico (car) e seu uso, cars isolados ou purificados, vetores, métodos para destruir células cancerígenas e polinucleotídeo
US20130280220A1 (en) 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
AU2013204923A1 (en) 2012-06-21 2014-01-16 Anthrogenesis Corporation Modified t lymphocytes having improved specificity
KR20210149195A (ko) 2012-07-13 2021-12-08 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 형질도입된 ｔ 세포의 투여 적합성을 평가하는 방법
HUE053439T2 (hu) 2012-08-20 2021-06-28 Hutchinson Fred Cancer Res Sejtes immunterápiára szolgáló eljárás és készítmények
MX367730B (es) 2012-09-04 2019-09-04 Cellectis Receptor de antigeno quimerico multi-cadena y usos del mismo.
EP2711418B1 (en) 2012-09-25 2017-08-23 Miltenyi Biotec GmbH Method for polyclonal stimulation of T cells by flexible nanomatrices
TW201414837A (zh) 2012-10-01 2014-04-16 Univ Pennsylvania 標定基質細胞以治療癌症之組合物和方法
EP2903637B1 (en) 2012-10-02 2019-06-12 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
WO2014055771A1 (en) 2012-10-05 2014-04-10 The Trustees Of The University Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
ES2824024T3 (es) 2012-10-10 2021-05-11 Sangamo Therapeutics Inc Compuestos modificadores de células T y usos de los mismos
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
AU2013204922B2 (en) 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
WO2014099671A1 (en) 2012-12-20 2014-06-26 Bluebird Bio, Inc. Chimeric antigen receptors and immune cells targeting b cell malignancies
EP3744736A1 (en) 2013-02-20 2020-12-02 Novartis AG Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
EP2970426B1 (en) 2013-03-15 2019-08-28 Michael C. Milone Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
JP2017505819A (ja) * 2014-02-04 2017-02-23 カイト ファーマ インコーポレイテッドＫｉｔｅ Ｐｈａｒｍａ， Ｉｎｃ Ｂ細胞悪性腫瘍及び他のがんの治療に有用な自己ｔ細胞を産生する方法、並びにその組成物
WO2015123527A1 (en) 2014-02-14 2015-08-20 Bellicum Pharmaceuticals, Inc. Methods for activating t cells using an inducible chimeric polypeptide
CA2945620C (en) 2014-04-14 2022-12-06 Cellectis Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
US10774343B2 (en) 2014-04-25 2020-09-15 Bluebird Bio, Inc. MND promoter chimeric antigen receptors
EP3134434A4 (en) 2014-04-25 2017-10-25 Bluebird Bio, Inc. Kappa/lambda chimeric antigen receptors
BR112016024957A2 (pt) 2014-04-25 2017-10-24 Bluebird Bio Inc métodos aperfeiçoados para fabricação de terapias celulares adotivas
DK3151672T3 (da) 2014-06-06 2021-02-01 Bluebird Bio Inc Forbedrede t-celle-sammensætninger
US10174095B2 (en) 2014-07-21 2019-01-08 Novartis Ag Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor
AU2015292590B2 (en) 2014-07-24 2020-01-16 2Seventy Bio, Inc. BCMA chimeric antigen receptors
SI3230321T1 (sl) 2014-12-12 2019-12-31 Bluebird Bio, Inc. BCMA himerni antigenski receptorji
WO2016164429A1 (en) * 2015-04-06 2016-10-13 The General Hospital Corporation Anti-cspg4 chimeric antigen receptors
WO2017099712A1 (en) 2015-12-07 2017-06-15 Bluebird Bio, Inc. Improved t cell compositions

Also Published As

Publication number Publication date
EP3151672A4 (en) 2018-01-17
EP3151672B1 (en) 2020-11-04
JP2017518052A (ja) 2017-07-06
KR20170007527A (ko) 2017-01-18
RU2719030C2 (ru) 2020-04-16
CN106793780B (zh) 2020-05-26
ZA201901336B (en) 2022-01-26
NZ726989A (en) 2020-08-28
WO2015188119A1 (en) 2015-12-10
HUE053101T2 (hu) 2021-06-28
RU2017100003A3 (lt) 2018-11-14
KR102485855B1 (ko) 2023-01-09
US20230193202A1 (en) 2023-06-22
SMT202100049T1 (it) 2021-03-15
JP6869390B2 (ja) 2021-05-12
PL3151672T3 (pl) 2021-05-31
ZA201608378B (en) 2019-06-26
CN106793780A (zh) 2017-05-31
SG10202108458XA (en) 2021-09-29
AU2015269197A1 (en) 2016-12-22
EP3828265A1 (en) 2021-06-02
AU2018274888B2 (en) 2019-12-05
IL249313A0 (en) 2017-02-28
CY1123823T1 (el) 2022-05-27
US10479975B2 (en) 2019-11-19
SG11201610170SA (en) 2017-01-27
HRP20210116T1 (hr) 2021-03-05
RU2020111566A (ru) 2020-05-19
MX2021002877A (es) 2021-06-04
JP2020072756A (ja) 2020-05-14
CN111394317B (zh) 2024-07-12
ES2846811T3 (es) 2021-07-29
RU2017100003A (ru) 2018-07-16
AU2015269197B2 (en) 2018-10-04
CA2951044A1 (en) 2015-12-10
DK3151672T3 (da) 2021-02-01
MX2016016076A (es) 2017-08-02
US11560547B2 (en) 2023-01-24
BR112016028644A2 (pt) 2017-08-22
JP6663359B2 (ja) 2020-03-11
BR112016028644B1 (pt) 2019-12-03
EP3151672A1 (en) 2017-04-12
AU2018274888A1 (en) 2018-12-20
US20200109365A1 (en) 2020-04-09
CA2951044C (en) 2023-10-03
US20170218337A1 (en) 2017-08-03
SI3151672T1 (sl) 2021-03-31
CN111394317A (zh) 2020-07-10
AU2018274888C1 (en) 2021-11-25
AU2020201489B2 (en) 2021-10-21
KR20230008915A (ko) 2023-01-16
SG10201810723VA (en) 2018-12-28
RS61406B1 (sr) 2021-03-31
PT3151672T (pt) 2021-02-02
AU2020201489A1 (en) 2020-03-19

Similar Documents

Publication Publication Date Title
ZA201901336B (en) Improved t cell compositions
IL274903A (en) cell
GB201410905D0 (en) Composition
GB201404178D0 (en) Composition
GB201403017D0 (en) Composition
GB201408167D0 (en) Compositions
IL251479A0 (en) components
GB201414910D0 (en) Composition
GB201403561D0 (en) Composition
GB201420306D0 (en) Compositions
GB201414555D0 (en) Composition
GB201410493D0 (en) Composition
HUE042287T2 (hu) Lítium-kén cella
SG11201610547WA (en) Solid composition
GB201415483D0 (en) Composition
GB201404390D0 (en) Composition
GB201403550D0 (en) Composition
GB201402648D0 (en) Composition
GB201502355D0 (en) Composition
GB201410934D0 (en) T cell
GB201419849D0 (en) Compositions
GB201421660D0 (en) Composition
GB201420629D0 (en) Composition
GB201416750D0 (en) Cell preparation
GB201412414D0 (en) Composition